Integrative Bioinformatics Analysis Reveals CHEK1 and UBE2C as Luminal A Breast Cancer Subtype Biomarkers

作者全名："Yu, Daowu; Liu, Shengwei; Chen, Yijun; Yang, Lumeng"

作者地址："[Yu, Daowu; Liu, Shengwei; Chen, Yijun; Yang, Lumeng] Chongqing Med Univ, Yongchuan Hosp, Chongqing, Peoples R China"

通信作者："Yang, LM (通讯作者)，Chongqing Med Univ, Yongchuan Hosp, Chongqing, Peoples R China."

来源：FRONTIERS IN GENETICS

ESI学科分类：MOLECULAR BIOLOGY & GENETICS

WOS号：WOS:000831756200001

JCR分区：Q2

影响因子：3.7

年份：2022

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：breast cancer; WGCNA; CHEK1; UBE2C; timer

摘要："In light of the limited number of targetable oncogenic drivers in breast cancer (BRCA), it is important to identify effective and druggable gene targets for the treatment of this devastating disease. Herein, the GSE102484 dataset containing expression profiling data from 683 BRCA patients was re-analyzed using weighted gene co-expression network analysis (WGCNA). The yellow module with the highest correlation to BRCA progression was screened out, followed by functional enrichment analysis and establishment of a protein-protein interaction (PPI) network. After further validation through survival analysis and expression evaluation, CHEK1 and UBE2C were finally identified as hub genes related to the progression of BRCA, especially the luminal A breast cancer subtype. Notably, both hub genes were found to be dysregulated in multiple types of immune cells and closely correlated with tumor infiltration, as revealed by Tumor Immune Estimation Resource (TIMER) along with other bioinformatic tools. Construction of transcription factors (TF)-hub gene network further confirmed the existence of 11 TFs which could regulate both hub genes simultaneously. Our present study may facilitate the invention of targeted therapeutic drugs and provide novel insights into the understanding of the mechanism beneath the progression of BRCA."

基金机构：Technology Innovation and Application Development Project of Chongqing [2021ZY3591]; Research Project of Yongchuan Hospital of Chongqing Medical University [YJSJ202132]

基金资助正文：Funding This work was supported by the Technology Innovation and Application Development Project of Chongqing Kewei United Chinese Medicine (2021ZY3591) and the Research Project of Yongchuan Hospital of Chongqing Medical University (YJSJ202132).